[11C]5-Hydroxy-tryptophan PET for Assessment of Islet Mass in Type 2 Diabetes

[11C]5-Hydroxy-tryptophan Positron Emission Tomography for Assessment of Islet Mass During Progression of Type 2 Diabetes

Cross-sectional study to investigate subjects at different stages of type 2 diabetes development with expected stratification of pancreatic islet mass. Non-diabetic individuals were assigned as control. The primary outcome was the [11C]5-hydroxy-tryptophan uptake and retention in the pancreas as a surrogate marker for the endogenous islet mass.

Inclusion Criteria:

• Type 2 diabetes fulfilling criteria for the four different study groups, or healthy volunteers

Exclusion Criteria:

• Ongoing pregnancy
• Renal failure (GFR<60 ml/min)
• Magnetic metal parts in the body
• Ongoing treatment with selective serotonin receptor inhibitors